Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
Heart Center, Turku University Hospital, and University of Turku, Turku, Finland.
Catheter Cardiovasc Interv. 2021 Mar;97(4):E560-E568. doi: 10.1002/ccd.29177. Epub 2020 Aug 7.
Conduction defects requiring permanent pacemaker (PPM) implantation are frequent complications occurring after surgical (SAVR) and transcatheter aortic valve replacement (TAVR).
Patients who underwent TAVR or SAVR with a bioprosthesis from the nationwide FinnValve registry were the subjects of this study. Patients with prior PPM, who received a sutureless prosthesis, or required cardiac resynchronization therapy or implantable cardioverter defibrillator were excluded from this analysis.
Four thousand and ten patients underwent SAVR and 1,897 underwent TAVR. TAVR had an increased risk of PPM implantation at 30-day (10.1% vs. 3.5%, unadjusted OR 3.11, 95%CI 2.56-3.87) and 5-year (15.7% vs. 8.6%, unadjusted SHR, 2.12, 95%CI 1.81-2.48) compared to SAVR. PPM implantation within 30 days from the index procedure did not increase the risk of 5-year mortality after either SAVR or TAVR. Among 1,042 propensity score matched pairs, TAVR had an increased risk of PPM implantation at 30-day (9.9% vs. 4.7%, p < .0001) and 5-year (14.7% vs. 11.4%, p = .001), but late (>30 days) PPM implantation at 5-year (4.7% vs. 6.9% SHR 0.72, 95%CI 0.47-1.10) was comparable to SAVR. The types of prosthesis had an impact on 30-day PPM implantation after TAVR, but not on late (>30 days) PPM implantation.
Although the risk of 30-day PPM implantation is higher after TAVR compared to SAVR, late (>30 days) PPM implantation was comparable with these treatment methods. PPM implantation within 30 days did not affect late survival.
在接受外科(SAVR)和经导管主动脉瓣置换术(TAVR)后,传导缺陷需要植入永久性起搏器(PPM)是常见的并发症。
本研究的对象是来自全国性 FinnValve 注册中心的接受 TAVR 或 SAVR 并使用生物假体的患者。排除了先前有 PPM、接受无缝线假体、需要心脏再同步治疗或植入式心脏复律除颤器的患者。
4010 例患者接受了 SAVR,1897 例患者接受了 TAVR。TAVR 在 30 天(10.1%比 3.5%,未调整的 OR 3.11,95%CI 2.56-3.87)和 5 年(15.7%比 8.6%,未调整的 SHR 2.12,95%CI 1.81-2.48)时植入 PPM 的风险增加。从索引手术到 30 天内植入 PPM 并不会增加 SAVR 或 TAVR 后 5 年死亡率的风险。在 1042 对倾向评分匹配的对中,TAVR 在 30 天(9.9%比 4.7%,p<0.0001)和 5 年(14.7%比 11.4%,p=0.001)时植入 PPM 的风险增加,但晚期(>30 天)5 年时的 PPM 植入率(4.7%比 SAVR 的 6.9% SHR 0.72,95%CI 0.47-1.10)相似。假体类型对 TAVR 后 30 天 PPM 植入有影响,但对晚期(>30 天)PPM 植入无影响。
虽然与 SAVR 相比,TAVR 后 30 天 PPM 植入的风险较高,但晚期(>30 天)PPM 植入与这些治疗方法相似。30 天内植入 PPM 不会影响晚期生存率。